Dublin, Oct. 13, 2016 -- Research and Markets has announced the addition of the "Stem Cell Assay Market by Type (Viability, Differentiation, Cell Identification), Kit (Mesenchymal, IPSCS, Hematopoietic), Product (Flow Cytometer, Detection Kit), Application (Regenerative Medicines, Drug Development), End User - Forecast to 2021" report to their offering.
The global stem cell assay market is expected to reach USD 1,363.3 million by 2021 from USD 536.6 million in 2016, at a CAGR of 20.5% from 2016 to 2021.
Factors such as high prevalence of chronic diseases, increasing investment in research related activities, and technological advancements are driving the growth in the global stem cell assay market. However, stringent regulatory policies and the high cost of stem cell based therapies are the major factors restraining the growth of this market.
The global stem cell assay market has been segmented on the basis of type of assay, kit, detection, instrument, application, end-user, and region. The viability/cytotoxicity segment is expected to account for the largest and fastest-growing segment of the global stem cell assay market in 2016. The increasing focus of the pharmaceutical industries on drug screening has resulted in the increase in demand for stem cell assays.
The major players in the global stem cell assay market include
- Bio Rad
- Cell Bio Labs, Inc.
- Cellular Dynamics International.
- GE Healthcare
- Hemogenix Inc.
- Merck Millipore
- Promega Corporation
- R&D Systems
- Stem Cell Technologies
- Thermo Fisher Scientific Pvt. Ltd
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Stem Cell Assay Market, By Technology
7 Stem Cell Assay Market, By Assay
8 Stem Cell Assay Market, By Kits
9 Stem Cell Assay Market, By Product
10 Stem Cell Assays Market, By Application
11 Stem Cell Assays, By End User
12 Regional Analysis
13 Competitive Landscape
14 Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/mj7nn6/stem_cell_assay
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Stem Cells


Anta Sports Expands Global Footprint With Strategic Puma Stake
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Washington Post Publisher Will Lewis Steps Down After Layoffs
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



